Axsome Therapeutics reported an early acceleration in adoption of AUVELITY following its June 2026 launch for agitation associated with dementia due to Alzheimer’s disease, with new-to-brand prescriptions among patients age 65 and older increasing 126% during the first eight weeks following launch.
The increase was measured against the comparable eight-week period during the prior quarter. Axsome views new-to-brand prescriptions as a leading indicator because they represent new patient starts. The company said initial adoption has also been supported by positive feedback from prescribers.
Overall AUVELITY new-to-brand prescriptions increased 26% from the first quarter. Approximately 266,000 total AUVELITY prescriptions were written during Q2, representing increases of 34% year over year and 12% sequentially. Payer coverage currently extends to approximately 89% of covered lives, including 82% of commercial lives and 100% of government lives.
AUVELITY generated $180.3 million of second-quarter net product sales, an increase of 51% year over year. Total Axsome net product revenue rose 46% to $218.4 million. SUNOSI generated $35.8 million, while SYMBRAVO sales reached $2.3 million.
Axsome is simultaneously advancing several late-stage neuroscience programs. The FDA accepted its NDA for AXS-12 for cataplexy in narcolepsy and assigned a May 1, 2027 PDUFA date. The company also expects Phase 3 ENGAGE results for solriamfetol in binge eating disorder during the fourth quarter of 2026.
KEY QUOTES:
“We expect our commercial momentum to build over the balance of the year, in particular with anticipated continued AUVELITY growth in Alzheimer’s disease agitation and major depressive disorder.”
Herriot Tabuteau, M.D., CEO of Axsome Therapeutics
